Top

Published in:

01-12-2012 | Research Article

The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents

Authors: Dimitra Florou, Konstantinos Mavridis, Andreas Scorilas

Published in: Tumor Biology | Issue 6/2012

Abstract

Gastric cancer constitutes one of the most common neoplasms globally. Kallikrein-related peptidases have attracted interest as potential tumor markers and future targets for novel cancer therapeutics. We have recently reported KLK13 clinical importance as a favorable prognostic biomarker for gastric cancer patients’ survival. By aiming to explore how the molecular profile of KLK13 is modified in stomach cancer cells treated with antineoplastic drugs, we examined, for the first time, the mRNA alterations of this gene following gastric cancer cells’ exposure to the prominent chemotherapeutic substances epirubicin, oxaliplatin, or methotrexate. The antiproliferative effects of these agents, on AGS cells’ growth, were determined by the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide and trypan blue assays. Total RNA, isolated from the harvested cells, was reverse-transcribed to cDNA. KLK13 levels were quantified via real-time PCR using the SYBR Green chemistry. The relative changes of KLK13 expression were calculated with the comparative C _t (2^−ddCt) method. Distinct KLK13 profiles resulted from AGS cells’ incubation with epirubicin or methotrexate for 24, 36, and 48 h. KLK13 expression increased in a time-dependent manner up to 5.70 times (for epirubicin) or 5.76 times (for methotrexate) at 48 h compared with the corresponding untreated cells. According to our results, KLK13 expression is implicated in the molecular pathways that are triggered after administration of anticancer agents on gastric cancer cells. Moreover, our data support the possibility that KLK13 may be exploited as a future molecular predictor of gastric cancer cells’ response to chemotherapy.

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92. doi:10.1093/annonc/mdl498.PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14(8):1149–55.PubMedCrossRef

Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12(20):3237–42.PubMed

Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15.PubMedCrossRef

Middleton G, Cunningham D. Current options in the management of gastrointestinal cancer. Ann Oncol. 1995;6 Suppl 1:17–25. discussion 25–16.PubMed

Khushalani N. Cancer of the esophagus and stomach. Mayo Clin Proc. 2008;83(6):712–22.PubMed

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. doi:10.1056/NEJMoa010187.PubMedCrossRef

Barone C, Cassano A, Pozzo C, D'Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology. 2004;67(1):48–53. doi:10.1159/000080285.PubMedCrossRef

10.

Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30. doi:10.1002/cncr.11660.PubMedCrossRef

11.

Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–73.PubMed

12.

Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 2000;58(5):920–7.PubMed

13.

Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005;8(2):86–94. doi:10.1007/s10120-005-0320-0.PubMedCrossRef

14.

Thomadaki H, Scorilas A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol Chem. 2008;389(11):1427–34. doi:10.1515/BC.2008.161.PubMedCrossRef

15.

Korbakis D, Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. Tumour Biol. 2009;30(2):100–7. doi:10.1159/000218160.PubMedCrossRef

16.

Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004;2(5):257–80.PubMed

17.

Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22(2):184–204.PubMedCrossRef

18.

Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001;382(1):5–14. doi:10.1515/BC.2001.002.PubMedCrossRef

19.

Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem. 2006;387(6):643–52. doi:10.1515/BC.2006.083.PubMedCrossRef

20.

Mavridis K, Talieri M, Scorilas A. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem. 2010;391(4):467–74. doi:10.1515/BC.2010.026.PubMedCrossRef

21.

Thomadaki H, Mavridis K, Talieri M, Scorilas A. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost. 2009;101(2):373–80.PubMed

22.

Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4(11):876–90. doi:10.1038/nrc1474.PubMedCrossRef

23.

Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007;249(1):61–79. doi:10.1016/j.canlet.2006.12.018.PubMedCrossRef

24.

Yousef GM, Chang A, Diamandis EP. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 2000;275(16):11891–8.PubMedCrossRef

25.

Petraki CD, Karavana VN, Diamandis EP. Human kallikrein 13 expression in normal tissues: an immunohistochemical study. J Histochem Cytochem. 2003;51(4):493–501.PubMedCrossRef

26.

Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS. 2003;111(1):225–32. discussion 232–223.PubMedCrossRef

27.

Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7. doi:10.1038/sj.pcan.4500674.PubMedCrossRef

28.

Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DH, Diamandis EP. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem. 2003;49(1):77–86.PubMedCrossRef

29.

White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009;101(7):1107–13. doi:10.1038/sj.bjc.6605280.PubMedCrossRef

30.

Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP. Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers. 2006;21(2):106–10.PubMed

31.

Planque C, Blechet C, Ayadi-Kaddour A, Heuze-Vourc'h N, Dumont P, Guyetant S, Diamandis EP, El Mezni F, Courty Y. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. Biol Chem. 2008;389(6):781–6. doi:10.1515/BC.2008.089.PubMedCrossRef

32.

Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, Diamandis EP. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer. 2002;86(9):1457–64. doi:10.1038/sj.bjc.6600283.PubMedCrossRef

33.

Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol. 2004;22(4):678–85. doi:10.1200/JCO.2004.05.144.PubMedCrossRef

34.

Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008;14(5):1355–62. doi:10.1158/1078-0432.CCR-07-4117.PubMedCrossRef

35.

Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43(15):1205–11. doi:10.1016/j.clinbiochem.2010.07.016.PubMedCrossRef

36.

Barranco SC, Townsend Jr CM, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, Gourley WK. Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res. 1983;43(4):1703–9.PubMed

37.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.PubMedCrossRef

38.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.PubMedCrossRef

39.

Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Taku K. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 2009;12(3):153–7. doi:10.1007/s10120-009-0517-8.PubMedCrossRef

40.

Kim HJ, Eun JY, Jeon YW, Yun J, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Won JH, Hong DS, Park HS. Efficacy and safety of oxaliplatin, 5-fluorouracil, and folinic acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer. Cancer Res Treat. 2011;43(3):154–9. doi:10.4143/crt.2011.43.3.154.PubMedCrossRef

41.

Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36(5):384–92. doi:10.1016/j.ctrv.2010.01.005.PubMedCrossRef

42.

Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol. 2010;26(6):640–6. doi:10.1097/MOG.0b013e32833efd9b.PubMedCrossRef

43.

van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564–70. doi:10.1038/nature06915.PubMedCrossRef

44.

Emami N, Diamandis EP. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol Oncol. 2007;1(3):269–87. doi:10.1016/j.molonc.2007.09.003.PubMedCrossRef

45.

Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem. 2010;391(5):505–11. doi:10.1515/BC.2010.056.PubMedCrossRef

46.

Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 2010;6(2):269–85. doi:10.2217/fon.09.149.PubMedCrossRef

47.

Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–17. doi:10.1515/hsz-2011-0260.PubMedCrossRef

48.

Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, Mori M. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11(19 Pt 1):6800–6. doi:10.1158/1078-0432.CCR-05-0943.PubMedCrossRef

49.

Feng B, Xu WB, Zheng MH, Ma JJ, Cai Q, Zhang Y, Ji J, Lu AG, Qu Y, Li JW, Wang ML, Hu WG, Liu BY, Zhu ZG. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol. 2006;21(10):1596–603. doi:10.1111/j.1440-1746.2006.04228.x.PubMedCrossRef

50.

Wen YG, Wang Q, Zhou CZ, Yan DW, Qiu GQ, Yang C, Tang HM, Peng ZH. Identification and validation of Kallikrein-related peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol. 2011;104(5):516–24. doi:10.1002/jso.21981.PubMedCrossRef

51.

Scorilas A, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: an open yet challenging road lies ahead. J Surg Oncol. 2011. doi:10.1002/jso.22041.

52.

Li M, Zhao ZW, Zhang Y, Xin Y Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer. Dig Dis Sci 56 (3):698–706. doi:10.1007/s10620-010-1346-7

53.

Huang W, Zhong J, Wu LY, Yu LF, Tian XL, Zhang YF, Li B. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett. 2007;251(1):78–85. doi:10.1016/j.canlet.2006.11.006.PubMedCrossRef

54.

Huang W, Tian XL, Wu YL, Zhong J, Yu LF, Hu SP, Li B. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. World J Gastroenterol. 2008;14(38):5810–5.PubMedCrossRef

55.

Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res. 2007;13(23):6984–92. doi:10.1158/1078-0432.CCR-07-1409.PubMedCrossRef

56.

Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafiropoulos N, Simillides G, Yiotakis A, Diamandis EP. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res. 2003;13(6–10):381–91.PubMed

57.

Chou RH, Lin SC, Wen HC, Wu CW, Chang WS Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun 409 (3):442–447. doi:10.1016/j.bbrc.2011.05.022

58.

Kapadia C, Ghosh MC, Grass L, Diamandis EP. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun. 2004;323(3):1084–90. doi:10.1016/j.bbrc.2004.08.206.PubMedCrossRef

59.

Yoon H, Blaber SI, Debela M, Goettig P, Scarisbrick IA, Blaber M. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem. 2009;390(4):373–7. doi:10.1515/BC.2009.026.PubMedCrossRef

60.

Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem. 2007;282(44):31852–64. doi:10.1074/jbc.M705190200.PubMedCrossRef

Title: The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents
Authors: Dimitra Florou
Konstantinos Mavridis
Andreas Scorilas
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0466-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Circulating miRNA is a novel marker for head and neck squamous cell carcinoma

miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway

Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis

Tumor-derived mesenchymal stem cells and orthotopic site increase the tumor initiation potential of putative mouse mammary cancer stem cells derived from MMTV-PyMT mice

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study

CD74: a potential novel target for triple-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer